infohep
  • Menu
  • Search
  • Home
  • News
  • About hepatitis
  • Countries
  • About us
  • Twitter
  • Facebook
  • RSS
  • Home
  • About hepatitis
  • Factsheets

Factsheets

  • Hepatitis C treatment factsheet: Daclatasvir (Daklinza)
  • Hepatitis C treatment factsheet: Epclusa (sofosbuvir + velpatasvir)
  • Hepatitis C treatment factsheet: Harvoni (sofosbuvir + ledipasvir)
  • Hepatitis C treatment factsheet: Maviret (glecaprevir + pibrentasvir)
  • Hepatitis C treatment factsheet: Simeprevir (Olysio)
  • Hepatitis C treatment factsheet: Sofosbuvir (Sovaldi)
  • Hepatitis C treatment factsheet: Viekirax (paritaprevir/ombitasvir/ritonavir) and Exviera (dasabuvir)
  • Hepatitis C treatment factsheet: Vosevi (sofosbuvir + velpatasvir + voxilaprevir)
  • Hepatitis C treatment factsheet: Zepatier (grazoprevir + elbasvir)

  • Contact us
  • Terms and conditions
  • Accessibility
  • Privacy and cookies

Latest hepatitis news

Sign-up for our monthly email bulletin Follow us on Twitter Find us on Facebook

The information on this website is intended to support, rather than replace, consultation with a healthcare professional.

©NAM Publications 2022. All rights reserved. We are not responsible for the content of external websites.

Company limited by guarantee. Registered in England & Wales, number: 2707596. Registered charity, number: 1011220

Infohep has been supported by a grant from Gilead Sciences Europe Ltd. Our funder has had no editorial control over the site’s content.

infohep

Latest treatment news and information for patient advocates and people working in hepatitis in Europe.

infohep is produced by NAM. Find out more about NAM

www.infohep.org/page//about-us/Find-out-about-NAM/page/2626330//